Cargando…

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease

INTRODUCTION: It is well known that infliximab (IFX) trough levels (TLs) are associated with endoscopic healing (EH) in Crohn’s disease (CD). We investigated whether IFX TLs are associated with transmural healing (TH) in pediatric patients with CD following 1-year treatment. METHODS: Pediatric patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, So Yoon, Kwon, Yiyoung, Choi, Sujin, Lee, So Mi, Choe, Byung-Ho, Kang, Ben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326720/ https://www.ncbi.nlm.nih.gov/pubmed/37426637 http://dx.doi.org/10.3389/fimmu.2023.1192827

Ejemplares similares

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
por: Jung, Jae Hoon, et al.
Publicado: (2022)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
por: Choi, Sujin, et al.
Publicado: (2021)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn’s disease
por: Wu, Yaling, et al.
Publicado: (2020)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Infliximab in the treatment of Crohn’s disease
por: Poggioli, Gilberto, et al.
Publicado: (2007)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn’s disease
por: Ma, Li, et al.
Publicado: (2021)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Infliximab to treat Crohn’s disease: an update
por: Cottone, M, et al.
Publicado: (2011)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease
por: Vaughan, Rose, et al.
Publicado: (2022)

Henoch-Schönlein purpura associated with infliximab therapy for pediatric Crohn’s disease
por: Li, Xiaolu, et al.
Publicado: (2022)

Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint?
por: Serban, Elena Daniela
Publicado: (2018)

Metastatic Crohn’s disease despite infliximab therapy
por: Campos, Sara, et al.
Publicado: (2017)

Myelolipoma After Infliximab Treatment for Crohn's Disease
por: Cesa, Kevin, et al.
Publicado: (2022)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1vltarams9ktle8pg9quqbma9g